Thus, the direct participations in biological regulation of immune responses in HCC and the ability of differential expressions to distinguish patient populations as biomarkers signify complement C4/C4a/C4b as important targets for disease modulation and therapeutic targeting. This evidence concerns the gene C4A and hepatocellular carcinoma.